Terumo Cardiovascular’s Post

How could a 9️⃣9️⃣.9️⃣9️⃣% reduction in bacterial adhesion on your vascular access catheters improve your patient outcomes? The data presented at the Association for Vascular Access Annual Meeting in 2023 and the Infusion Nurses Society Annual Meeting in 2024 strongly supports MIMIX®️ technology in achieving this goal. We invite you to explore this compelling evidence and our multiple clinical studies. Please reach out at https://loom.ly/ElpFRfM *While in vitro data is valuable, it doesn’t always predict clinical outcomes. #vascularaccess #datadriven #patientoutcomes

At #PrediSurge, our mission is to enhance clinical outcomes by enabling physicians to assess and manage the risks associated with cardiovascular procedures more effectively. Our PlanOp™ Aortic ERI leverages patient-specific simulations of infrarenal stent-graft implantations to accurately predict the risk of type 1A Endoleak in standard EVAR procedures. The integration of PlanOp™ Aortic ERI into their practice could lead physicians to: ✅ Significantly reduce the risk of reintervention. ✅ Streamline and expedite the cardiovascular procedure process. ✅ Improve the overall workflow of procedures, leading to better patient outcomes. Discover how PlanOp™ Aortic ERI is transforming cardiovascular care at PrediSurge: www.predisurge.com 🌐 #cardiovascular #care #digital #solutions #planop #clinicians #technology #EVAR #endoleaks

Make the diagnosis in our new #interactive case series using real-life cases from board-certified ophthalmologists, physicians will walk through cases presented in clinical practice today. Starting with patient presentations featuring clinical photos from the latest OCT technology, physicians can click on the most likely diagnosis/prognosis and best therapeutic approach, before learning the actual findings and reading a short discussion about the case and condition. #Ophthalmology #OCT #ClinicalDiagnosis #TopconHealthcare

Two devices might look very similar -but in reality, the impact they have on patients and clinicians is very different based on their outcomes. The Access Vascular MIMIX® technology demonstrated 99.999%* less bacterial adhesion than a plain (standard) polyurethane PICC with an in vitro study (LeRoy K, AVA 2023) and 6X fewer complications based on published clinical data (Bunch, J; J of Inf Nursing, 2022). Review our data here: https://loom.ly/ElpFRfM and contact us to learn more https://loom.ly/gSt1u8E *Pre-clinical in vitro valuations do not necessarily predict clinical performance with respect to thrombus formation. #Vascularaccess #Datadriven #AccessVascular

Without question the best patient support in the SCS market.

Make the diagnosis in our new #interactive case series using real-life cases from board-certified ophthalmologists, physicians will walk through cases presented in clinical practice today. Starting with patient presentations featuring clinical photos from the latest OCT technology, physicians can click on the most likely diagnosis/prognosis and best therapeutic approach, before learning the actual findings and reading a short discussion about the case and condition. #Ophthalmology #OCT #ClinicalDiagnosis #TopconHealthcare

Lawrence Eichenfield, MD, investigates the efficacy, physician satisfaction, treatment patterns, and outcomes of topical ruxolitinib, a novel therapy for atopic dermatitis, through the review of two recently presented clinical trials.Explore the series: https://ow.ly/rsOU50SleEh

Discover how CVL’s practices are at the forefront of cardiovascular medicine innovation! 🚀 From cutting-edge technology to advanced patient care models, learn how we're driving change and improving patient outcomes. Read our latest blog post: https://hubs.la/Q02GCRhL0 #CardiovascularInnovation #HealthcareRevolution #CVL

Unlocking new horizons in critical care, Cytosorb emerges as a pivotal player in managing hyperbilirubinemia. Elevating patient care standards, this breakthrough technology efficiently removes bilirubin and toxins from the bloodstream. Hyperbilirubinemia, a condition characterized by elevated bilirubin levels, poses significant challenges in conditions like liver dysfunction and hemolysis. Cytosorb's innovative hemoadsorption capability intercepts bilirubin as blood flows through, alleviating symptoms such as jaundice and pruritus while mitigating potential neurological complications. Integrated seamlessly into treatment regimens, especially in acute liver failure or sepsis-associated liver dysfunction scenarios, Cytosorb complements comprehensive approaches, offering vital support to liver function and enhancing patient outcomes. As research expands and clinical insights deepen, Cytosorb's versatility in managing hyperbilirubinemia underscores its transformative potential in critical care. Healthcare professionals harness its power to tailor treatment strategies, ensuring optimal patient care. Explore the frontier of critical care with Cytosorb and revolutionize patient outcomes. #Cytosorb #CriticalCare #HyperbilirubinemiaManagement #InnovativeTechnology #PatientCareExcellence

ICYMI: We spoke with Deepak L. Bhatt, MD, MPH on the topic of in-hospital initiation of GDMT in #HeartFailure. Check out the preview below and follow along for the latest insight in #cardiovascular medicine. https://lnkd.in/eNu63P43